TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03860519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes
Description: Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NorthShore Connect Real Time ICS and SABA Usage Feedback - No
Description: Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes
Description: Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No
Description: Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
Study: NCT03441412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: 2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated.
Study: NCT02285101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-BCT-100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-BCT-100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-BCT-100
Study: NCT02348216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert
Study: NCT01440023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Response Inhibition Training
Description: Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
Study: NCT01440023

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized Placebo Cognitive Training
Description: Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
Study: NCT02194231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
Study: NCT00837031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
Study: NCT00837577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to sitagliptin once daily for 12 weeks (double-blind period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose
Description: All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose
Description: All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study.
Study: NCT02345863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101
Description: Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily
Study: NCT04676919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phonophoresis therapy with pulsed mode ultrasound
Description: phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phonophoresis therapy with continuous mode ultrasound
Description: phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham ultrasound
Description: sham ultrasound therapy, five days a week for three weeks
Study: NCT02156466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010841
Description: MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010841
Description: MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010841
Description: MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010841
Description: MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study: NCT00515385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Study: NCT02348216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administered according to package insert
Study: NCT00515385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Study: NCT02348216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered according to package insert
Study: NCT00525317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)
Description: 120 mg x 3 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)
Description: 120 mg x 3 or placebo
Study: NCT03663075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group information (GI)
Description: The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group information (GI)
Description: The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured person-centered support (PCS)
Description: The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured person-centered support (PCS)
Description: The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
Study: NCT00918294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickOpt
Description: The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
Study: NCT03871387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep Group
Description: * Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: * Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2
Study: NCT00125216

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Response Elaboration Training
Description: Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
Study: NCT03286491

Intervention type: DIAGNOSTIC_TEST
Intervention: Further cardiac imaging
Description: Study patients will be reviewed whether they will have coronary interventions in 30 days
Study: NCT01679535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition and hygiene education
Description: Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
Study: NCT02740348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ZocDoc Assistance
Description: Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ZocDoc Information
Description: Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
Study: NCT02417246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brand name metoprolol ER
Description: This medication will be taken for 7 to 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brand name metoprolol ER
Description: This medication will be taken for 7 to 28 days
Study: NCT00515385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Single IV dose
Study: NCT02417246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic A
Description: This medication will be taken for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic A
Description: This medication will be taken for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic B
Description: This medication will be taken for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic B
Description: This medication will be taken for 7 days
Study: NCT04483479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Investigational Treatment ENT-01
Description: ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
Study: NCT00759109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation (no treatment)
Description: No treatment was given to participants enrolled in the control arm (Arm B).
Study: NCT01889420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle.
Study: NCT00515385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Single IV dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose
Study: NCT01186952

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet intervention and structured exercise training program
Description: Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
Study: NCT02579369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem cells
Description: Dressing for Dystrophic Epidermolysis Bullosa wound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyurethene Film
Description: Dressing for Dystrophic Epidermolysis Bullosa wound.
Study: NCT01532037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy based self help
Description: Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy based self help
Description: Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Usual care from healthcare professionals with regard to patients symptoms of fatigue
Study: NCT04274088

Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Phacoemulsification surgery

Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Phacoemulsification surgery
Study: NCT02380066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Placebo